LivaNova Stock Price, News & Analysis (NASDAQ:LIVN)

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month target prices for LivaNova's shares. Their LIVN share price targets range from $52.00 to $62.00. On average, they expect the company's stock price to reach $58.60 in the next year. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.

LivaNova's stock was trading at $55.54 at the beginning of 2023. Since then, LIVN stock has decreased by 16.4% and is now trading at $46.43.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our LIVN earnings forecast.

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.09. The firm had revenue of $286.10 million for the quarter, compared to analyst estimates of $271.97 million. LivaNova had a trailing twelve-month return on equity of 12.10% and a net margin of 0.27%. The company's quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the business earned $0.58 EPS.

ETFs with the largest weight of LivaNova (NASDAQ:LIVN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Nasdaq Future Gen 200 ETF (QQQS), IQ Healthy Hearts ETF (HART), Simplify Health Care ETF (PINK), Global X Aging Population ETF (AGNG), Invesco S&P MidCap 400 GARP ETF (EWMC) and iShares U.S. Medical Devices ETF (IHI).JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

LivaNova's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (10.74%), Victory Capital Management Inc. (1.86%), Ameriprise Financial Inc. (1.70%), Loomis Sayles & Co. L P (1.63%), Hawk Ridge Capital Management LP (1.60%) and Barclays PLC (1.58%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends.

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.